These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 16218177

  • 1. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
    Lebray P, Nalpas B, Vallet-Pichard A, Broissand C, Sobesky R, Serpaggi J, Fontaine H, Pol S.
    Antivir Ther; 2005; 10(6):769-76. PubMed ID: 16218177
    [Abstract] [Full Text] [Related]

  • 2. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, Sjogren M, Farmer D, Ramsey L, Terra K, Gujral H, Gurung C, Srishord M, Fang Y.
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Koskinas J, Zacharakis G, Sidiropoulos J, Elefsiniotis J, Savvas S, Kotsiou S, Kountouras D, Schina M, Kostopoulos P, Archimandritis A.
    J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
    [Abstract] [Full Text] [Related]

  • 4. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM.
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment.
    Van Vlerken LG, Van Soest H, Janssen MP, Boland GJ, Drenth JP, Burger DM, Siersema PD, Van Erpecum KJ.
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1308-15. PubMed ID: 20729740
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin.
    Talal AH, Liu RC, Zeremski M, Dimova R, Dove L, Pearce D, Hassanein T, Doonquah L, Aboulafia D, Rodriguez J, Bonilla H, Galpin J, Aberg JA, Johnston B, Glesby MJ, Jacobson IM.
    J Acquir Immune Defic Syndr; 2011 Nov 01; 58(3):261-8. PubMed ID: 21876446
    [Abstract] [Full Text] [Related]

  • 10. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
    Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA, Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas.
    Antivir Ther; 2007 Nov 01; 12(8):1225-35. PubMed ID: 18240862
    [Abstract] [Full Text] [Related]

  • 11. Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
    Tarantino L, De Rosa A, Tambaro O, Ripa C, Celiento M, Schiano A.
    Infez Med; 2009 Mar 01; 17(1):20-3. PubMed ID: 19359820
    [Abstract] [Full Text] [Related]

  • 12. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP, Younossi ZM.
    Cleve Clin J Med; 2004 May 01; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis.
    Bertino G, Ardiri A, Boemi PM, Calvagno GS, Ruggeri IM, Speranza A, Santonocito MM, Ierna D, Bruno CM, Valenti M, Boemi R, Naimo S, Neri S.
    Eur J Clin Pharmacol; 2010 Oct 01; 66(10):1055-63. PubMed ID: 20652232
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin.
    Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ, HCV Natural History Study Group.
    Am J Gastroenterol; 2005 Feb 01; 100(2):299-307. PubMed ID: 15667486
    [Abstract] [Full Text] [Related]

  • 17. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 18. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.
    Am J Gastroenterol; 2005 Nov 02; 100(11):2447-52. PubMed ID: 16279899
    [Abstract] [Full Text] [Related]

  • 19. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
    Pau AK, McLaughlin MM, Hu Z, Agyemang AF, Polis MA, Kottilil S.
    AIDS Patient Care STDS; 2006 Sep 02; 20(9):612-9. PubMed ID: 16987047
    [Abstract] [Full Text] [Related]

  • 20. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
    Donnerer J, Grahovac M, Stelzl E, Kessler HH, Bankuti C, Stadlbauer V, Stauber RE.
    Pharmacology; 2006 Sep 02; 76(3):136-40. PubMed ID: 16410679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.